Drug development: The invisible front line

Meredith Wadman
Additional contact information
Meredith Wadman: Meredith Wadman is a biomedical reporter for Nature in Washington DC.

Nature, 2010, vol. 467, issue 7317, 786-786

Abstract: The paid participants in phase I clinical trials need more protection, finds Meredith Wadman.

Date: 2010
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/467786a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:467:y:2010:i:7317:d:10.1038_467786a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/467786a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().